79.64MMarket Cap-508P/E (TTM)
1.520High1.510Low13.26KVolume1.520Open1.490Pre Close20.13KTurnover0.04%Turnover RatioLossP/E (Static)52.74MShares17.82552wk High0.58P/B46.99MFloat Cap1.19052wk Low--Dividend TTM31.12MShs Float117.450Historical High--Div YieldTTM0.67%Amplitude1.190Historical Low1.517Avg Price1Lot Size
ALX Oncology Stock Forum
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced tha...
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from...
Please close above the 20
No comment yet